<p fr-original-style="" style="margin-top: 0px; margin-bottom: 1em; box-sizing: border-box;">• <a fr-original-style="" href="https://www.bloomberg.com/news/articles/2022-06-02/regeneron-buys-cancer-drug-from-sanofi-for-up-to-1-1-billion" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank"><strong fr-original-style="" style="font-weight: 700; box-sizing: border-box;">US-based Regeneron Pharmaceuticals</strong></a> agreed to buy the rights to the cancer drug Libtayo from its French partner Sanofi, for as much as $1.1 billion (€1bn) — by paying $900 million upfront and $200 million in milestone payments if the drug reaches certain regulatory and sales targets.</p>

Regeneron Pharmaceuticals ile ilgili hikayeler